What is Targan?
Targan is dedicated to enhancing production yields for producers by offering solutions that eliminate the need for antibiotics and chemicals. The company leverages a sophisticated suite of state-of-the-art technologies designed to ensure both efficiency and humane production practices. This focus positions Targan as a key player in advancing sustainable and ethical production methods.
How much funding has Targan raised?
Targan has raised a total of $100M across 1 funding round:
Private Equity
$100M
Private Equity (2026): $100M with participation from Symbiotic Capital
Key Investors in Targan
Symbiotic Capital
Symbiotic Capital, based in Los Angeles, California, specializes in healthcare credit solutions, supporting scientific communities with financial resources tailored for the healthcare industry. They focus on integrating scientific principles into innovative credit offerings.
What's next for Targan?
The recent major strategic investment signals a pivotal growth phase for Targan. This capital infusion is expected to accelerate the development and deployment of its advanced technological solutions, further solidifying its market presence and expanding its operational reach. Targan is poised to continue its trajectory of innovation, driving efficiency and sustainability in production.
See full Targan company page
